Problem with metal and plastic, or ceramic joint replacements is that they fail over time. In other words, they don't last forever. Researchers from the University of Missouri and Columbia University have developed a way to create biological joints in animals. Read more...
Researchers found that the adult lifetime risk in the United States of having some type of inflammatory autoimmune disease is 8.4% for women and 5.1% for men -- considered to be substantial. They also determined lifetime risk for specific diseases. Read more...
The FDA has added supplemental labeling to Actemra, a Roche/Genentech drug developed for the treatment of rheumatoid arthritis. The supplemental labeling was based on positive data coming out of the Phase III LITHE trial. What wording was added? Read more...
Do you feel vulnerable because you are disabled by arthritis -- at high risk to be ripped off, cheated, scammed? Have you actually been ripped off and felt your disability was a contributing factor? When you meet a repairman at the front door, does the price of the repair go up once he sees you are struggling with pain? Do they look at you and jack up the price -- knowing you want them to get in, get it done, and get out? Do they sense you don't feel like haggling? Share You Experience...
Sign up for more free newsletters on your favorite topics
You are receiving this newsletter because you subscribed to the About Arthritis newsletter. If you wish to change your email address or unsubscribe, please click here.
Problem with metal and plastic, or ceramic joint replacements is that they fail over time. In other words, they don't last forever. Researchers from the University of Missouri and Columbia University have developed a way to create biological joints in animals. 
Researchers found that the adult lifetime risk in the United States of having some type of inflammatory autoimmune disease is 8.4% for women and 5.1% for men -- considered to be substantial. They also determined lifetime risk for specific diseases. 
The FDA has added supplemental labeling to Actemra, a Roche/Genentech drug developed for the treatment of rheumatoid arthritis. The supplemental labeling was based on positive data coming out of the Phase III LITHE trial. What wording was added? 
No comments:
Post a Comment